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Receptor tyrosine kinases (RTKs) regulate critical cell signaling pathways, yet the properties of their
cognate ligands that inﬂuence receptor activation are not fully understood. There is great interest in
parsing these complex ligand–receptor relationships using engineered proteins with altered binding
properties. Here we focus on the interaction between two engineered epidermal growth factor (EGF)
mutants and the EGF receptor (EGFR), a model member of the RTK superfamily. We found that EGF
mutants with faster kinetic on-rates stimulate increased EGFR activation compared to wild-type
EGF. These ﬁndings support previous predictions that faster association rates correlate with
enhanced receptor activity.
Structured summary of protein interactions:
humanEGFR binds to humanEGF by surface plasmon resonance (View Interaction 1, 2, 3)
mouseEGFR binds to humanEGF by surface plasmon resonance (View Interaction 1, 2, 3)
humanEGFR physically interacts with humanEGF by ﬂuorescence-activated cell sorting (View Interac-
tion 1, 2, 3, 4, 5, 6, 7)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Epidermal growth factor (EGF) is a 53 amino acid polypeptide
that stimulates a variety of cellular processes, including prolifera-
tion, survival, and differentiation [1]. Binding of EGF to its receptor
(EGFR, ErbB1) induces receptor dimerization, leading to activation
of the receptor intracellular tyrosine kinase domain and initiation
of pleiotropic downstream signaling pathways [2]. After activation,
EGF ligand–receptor complexes are rapidly internalized and traf-
ﬁcked through the cell, where they are ultimately targeted for
recycling or degradation [3]. Therefore, EGFR signaling potency is
regulated by both ligand binding properties and receptor trafﬁck-
ing patterns [4]; however, understanding the interplay between
these processes remains a signiﬁcant challenge. Although somechemical Societies. Published by E
, EGF receptor; RTK, receptor
rive, James H. Clark Center,
5 2952.
. Cochran).studies have found a correlation between EGF binding afﬁnity
and biological activity, recent ﬁndings have demonstrated that this
trend is not always present [5–9]. Other subtleties of EGF–EGFR
interactions, such as binding kinetics and pH sensitivity, can also
inﬂuence the magnitude and duration of the signaling response.
Computational modeling studies suggested the importance of
binding on-rates to receptor activation [10], as the rapid internal-
ization and subsequent degradation of EGF ligand-receptor com-
plexes can impose a limit on activation that is independent of
binding off-rates [11]. Furthermore, the pH sensitivity of the
EGF–EGFR interaction inﬂuences the fraction of internalized recep-
tor that is recycled back to the cell surface for continued signaling
[3,12].
To develop a molecular toolkit for studying EGF–EGFR inter-
actions, we previously used combinatorial methods to engineer
EGF mutants with 4- to 30-fold increased receptor binding afﬁn-
ity [13]. Here, we selected two of these clones, mutant 28 (m28)
and mutant 123 (m123) (Table 1), for further characterization
due to their high soluble expression levels in yeast. We showed
that these mutants retain their binding speciﬁcities for EGFR
compared to other ErbB family members, have stronger EGFR
binding afﬁnities resulting from increased kinetic on-rates, andlsevier B.V. All rights reserved.
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binding properties translated into enhanced EGFR activation
responses. To our knowledge this work is the ﬁrst experimental
validation of ligands with faster binding on-rates exhibiting
increased receptor activation.
2. Materials and methods
For additional materials and methods, see Supplementary data.
2.1. Cell binding assays
Equilibrium receptor binding afﬁnities were measured on
NR6WT and BJ-5ta ﬁbroblast cells after incubation with EGF
(threefold dilutions from 200 nM to 10 pM) for 6 h at 4 C. Cells
were labeled with a FITC-conjugated antibody directed against an
N-terminal FLAG epitope tag on EGF and analyzed using a FACSCal-
ibur ﬂow cytometer (BD Biosciences). Receptor binding off-rates
were measured using NR6WT cells pretreated for 20 min with
100 lM phenylarsine oxide to inhibit EGFR internalization. Cells
were incubated with 25 nM EGF for 10 min at 37 C, washed, and
incubated in serum-free medium at 37 C for times ranging from
30 min to 7 h. The level of EGF persisting on the cell surface was
measured by ﬂow cytometry as above.
2.2. Surface plasmon resonance assays
EGF binding interactions with immobilized human (hEGFR) and
murine EGFR (mEGFR) were analyzed by surface plasmon reso-
nance (SPR) using a Biacore 3000 instrument (Biacore Life Sci-
ences). Kinetic experiments were performed at 25 C in degassed
running buffer. EGF analyte at various concentrations (twofold
dilutions from 400 nM to 780 pM) was ﬂowed over EGFR-immobi-
lized surfaces at 30 ll/min for 2 min. Final sensorgrams were ana-
lyzed with BIAevaluation software (Biacore Life Sciences) and
simultaneously ﬁt for afﬁnity and kinetic parameters using a 1:1
Langmuir binding model.Fig. 1. Binding of wild-type EGF, mutant 28, and mutant 123 to EGFR expressed on the ce
cells. (C) Off-rates of EGF binding to EGFR on NR6WT cells. EGFwt (s, solid line), m28 (j
triplicate and error bars denote standard error of the mean.
Table 1
Amino acid sequences of wild-type EGF, mutant 28, and mutant 123. Mutations are
underlined in bold type.
Clone Sequence
EGFwt NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR
m28 NSDSECPLSHDGYCLHGGVCMYIKAVDRYACNCVVGYIGERCQYRDLTWWGPR
m123 NSYSECPPSYDGYCLHDGVCRYIEALDSYACNCVVGYAGERCQYRDLRWWGRR2.3. EGFR activation and immunoblotting
BJ-5ta ﬁbroblasts were pretreated with 1 mM Na3VO4 phospha-
tase inhibitor and incubated with EGF (ﬁvefold dilutions from 20
nM to 6.4 pM) for 15 min at 37 C. Cells were treated with lysis
buffer supplemented with 1 mM Na3VO4 and protease inhibitors.
Cell lysates were resolved by SDS–PAGE under reducing conditions
and analyzed by western blot with primary antibodies directed
against actin or phosphorylated or total EGFR and a horseradish
peroxidase-conjugated secondary antibody. Western blots were
developed using chemiluminescence and imaged using a Chemidoc
System (BioRad).
2.4. EGFR downregulation assays
BJ-5ta ﬁbroblasts were treated with 0.1 nM EGF for times rang-
ing from 15 min to 6 h. Post-stimulation, cells were ﬁxed with 1.5%
paraformaldehyde, and cell-surface EGFR was analyzed by ﬂow
cytometry using a primary antibody directed against EGFR and a
secondary R-phycoerythrin-conjugated antibody.
3. Results
3.1. EGF mutants bind speciﬁcally to EGFR and not to other ErbB
receptors
EGFR is one of four receptors in the ErbB family, which also in-
cludes ErbB2, ErbB3, and ErbB4. We measured the ErbB binding
speciﬁcity of m28 and m123 compared to wild-type EGF (EGFwt)
using stably-transfected CHO cells individually expressing each
of the four ErbB receptors. We found that EGFwt and the engi-
neered mutants bound speciﬁcally to EGFR but not to other ErbB
receptor family members (Fig. S1), demonstrating that the amino
acid mutations conferring high-afﬁnity binding to EGFR do not
alter binding speciﬁcity.
3.2. EGF mutants bind cell surface EGFR with higher afﬁnity than wild-
type EGF
We next determined equilibrium binding afﬁnities (KD) of
EGFwt, m28, and m123 to EGFR expressed on ﬁbroblasts and con-
ﬁrmed that the mutants bound with stronger afﬁnity (Fig. 1A and
B, and Table 2). Compared to EGFwt, m28 and m123 bound eight-
fold more tightly to EGFR on NR6WT cells. On BJ-5ta cells, m28 and
m123 bound 37- and 33-fold more tightly, respectively, than
EGFwt. We also found that the kinetic off-rates (koff) of binding
of EGFwt and mutants to NR6WT cells was comparable (Fig. 1Cll surface. Equilibrium binding titrations of EGF to EGFR on (A) NR6WT and (B) BJ-5ta
, dashed line), and m123 (, dotted line). Binding experiments were performed in
Table 2
Equilibrium binding afﬁnities and kinetic rates of wild-type EGF, mutant 28, and
mutant 123 binding to cell-surface EGFR. Numbers in parenthesis denote fold-change
over EGFwt.
EGFwt m28 m123
NR6WT cells
KD (pM) 600 ± 200 80* ± 20 (8) 80* ± 50 (8)
koff (s1)  104 4.3 ± 0.8 2.60 ± 0.08 (1.7) 2.8 ± 0.4 (1.5)
kon (M1 s1)  105 7 30 (4) 40 (6)
BJ-5ta cells
KD (pM) 1100 ± 200 30* ± 6 (37) 34* ± 7 (33)
* Statistical signiﬁcance (P < 0.05) compared to EGFwt.
Table 3
Equilibrium binding afﬁnities and kinetic rates of wild-type EGF, mutant 28, and
mutant 123 binding to human and murine EGFR extracellular domain by SPR.
Numbers in parenthesis denote fold-change over EGFwt.
EGFwt m28 m123
Human EGFR
KD (nM) 90 ± 10 6* ± 2 (15) 4.9* ± 0.3 (18)
koff (s1)  103 18 ± 1 11* ± 2 (1.6) 12.4* ± 0.6 (1.5)
kon (M1 s1)  105 2.0 ± 0.2 20* ± 8 (10) 25* ± 1 (13)
Murine EGFR
KD (nM) 18 ± 1 4.5* ± 0.2 (4.0) 2.27* ± 0.05 (7.9)
koff (s1)  103 2.7 ± 0.2 2.14* ± 0.08 (1.3) 4.0* ± 0.1 (0.7)
kon (M1 s1)  105 1.47 ± 0.03 4.76* ± 0.07 (3.2) 17.6* ± 0.8 (12.0)
* Statistical signiﬁcance (P < 0.05) compared to EGFwt.
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expected on-rates (kon) of receptor binding were determined
(KD = koff/kon) to be approximately four and sixfold faster for m28
and m123, respectively, compared to EGFwt.
3.3. EGF mutants bind EGFR extracellular domain with faster kinetic
on-rates than wild-type EGF
Real-time interactions of wild-type and mutant EGF with hEGFR
and mEGFR were analyzed by SPR (Fig. 2 and Table 3). In these
experiments, m28 and m123 bound 15- and 18-fold more tightly
to hEGFR, respectively, than EGFwt. In addition, EGFwt bound to
mEGFR with higher afﬁnity than hEGFR. Compared to EGFwt,
m28 and m123 bound four and eightfold more tightly to mEGFR,
respectively. Since the EGF mutants were afﬁnity-matured against
human EGFR, it was not surprising that the difference between
wild-type and mutant EGF binding to mEGFR was not as great as
for hEGFR. For both mutants, improvements in KD over EGFwt re-
sulted primarily from increased kon rather than decreased koff (Ta-
ble 3), in agreement with cell surface studies above. Differences
observed in absolute values of binding parameters from cell sur-
face and SPR studies occur due to the removal of membrane con-
straints in SPR experiments, which use only EGFR extracellular
domain [14].
The pH sensitivity of the binding interaction of EGF ligands
(200 nM) with hEGFR and mEGFR was measured by SPR over pH
values ranging from 5.0 to 8.5. Measurement of the steady-stateFig. 2. Binding of wild-type EGF, mutant 28, and mutant 123 to the extracellular domain
by surface plasmon resonance. Binding experiments were performed in triplicate and rebinding responses for each ligand–receptor pair across various
pH values revealed that the interactions of EGFwt and m28 with
EGFR were sensitive to changes in pH, while the binding of m123
with EGFR was much less so (Fig. S2).
3.4. EGF mutants more strongly activate EGFR compared to wild-type
EGF
We next measured the ability of wild-type and mutant EGF to
activate EGFR on ﬁbroblasts. We found that m28 and m123 more
strongly stimulated EGFR phosphorylation in these cells at lower
concentrations than EGFwt (Fig. 3A). Since EGFR is rapidly internal-
ized into the cell upon activation of the intracellular tyrosine ki-
nase domain [15], downregulation of the receptor can serve as a
surrogate measurement for receptor activation. Treatment of ﬁbro-
blasts with m28 and m123 induced signiﬁcantly increased EGFR
downregulation compared to EGFwt, further indicating that the
EGF mutants more strongly activate cell-surface EGFR (Fig. 3B).
4. Discussion
We measured the EGFR binding afﬁnities and kinetic rate con-
stants of two previously identiﬁed EGF mutants, m28 and m123
[13]. We showed through cell surface measurements and SPR
that m28 and m123 have increased binding afﬁnity for EGFRof human and murine EGFR. EGF binding to (A) hEGFR or (B) mEGFR was measured
presentative titration series sensorgrams are shown.
Fig. 3. Activation of EGFR by wild-type EGF, mutant 28, and mutant 123. (A) Western blot analysis of phosphorylated EGFR (p-EGFR, top panel), total EGFR (EGFR, middle
panel) and actin loading control (actin, lower panel) in BJ-5ta cells after treatment with EGF. (B) Downregulation of cell-surface EGFR in BJ-5ta cells in response to EGF
stimulation. EGFwt (s, solid line), m28 (j, dashed line), or m123 (, dotted line). Experiments were performed in triplicate and error bars denote standard error of the mean.
⁄ Statistical signiﬁcance (P < 0.05) compared to EGFwt.
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association rates of m28 and m123 were surprising since both mu-
tants were discovered by screening combinatorial libraries under
equilibrium binding conditions, which typically isolates mutants
with decreased dissociation rates. We showed that m28 and
m123 elicited increased EGFR activation compared to EGFwt, as
measured by phosphorylation of the receptor tyrosine kinase
(RTK) domain and receptor downregulation. Interestingly, m123
had stronger binding at low pH compared to m28 and EGFwt. This
difference implied that m123 might induce more intracellular
receptor degradation compared to m28, yet both mutants exhib-
ited greater levels of EGFR downregulation compared to EGFwt,
suggesting that cell surface binding events drive this biological
response.
Because of its important biological role, there has been much
interest in EGF mutants with enhanced cell signaling for applica-
tions in wound healing and regenerative medicine [16,17]. Previ-
ous attempts at engineering EGF [5,7–9] had mixed success, but
highlighted the complex relationship between ligand binding and
EGFR activation. While some studies concluded that receptor acti-
vation is directly proportional to equilibrium binding afﬁnity [5,9],
others found that equivalent or enhanced potency can be attained
by EGF mutants with weaker receptor binding interactions than
EGFwt [7,8]. Computational studies of cellular signaling and traf-
ﬁcking processes coupled to the activation of transmembrane
receptors have attempted to explain these inconsistencies by high-
lighting the importance of receptor binding on-rates [10,18].
To our knowledge, our work represents the ﬁrst experimental
corroboration of the effects of increased ligand binding on-rates
with enhanced receptor activation. We demonstrated that EGF mu-
tants with faster association rates, but nearly equivalent dissocia-
tion rates, more strongly activated EGFR compared to EGFwt.
Collectively, these studies suggest that while receptor activity is
linked to ligand binding, the magnitude of the response can be al-
tered solely by differences in the association rate of the interaction.
Furthermore, these results suggest a general strategy for engineer-
ing ligands that stimulate enhanced receptor activity [19].
While m28 and m123 stimulate increased EGFR activation, this
attribute may not correlate with enhanced agonistic potential,
since increased EGFR activation and downregulation could result
in decreased or unaffected biological outcomes due to signal atten-
uation [3]. This consideration is also coupled with unaltered (m28)or decreased (m123) pH binding sensitivities, which are expected
to inﬂuence receptor recycling. In future studies, it will therefore
be interesting to explore the effects of increased EGFR phosphory-
lation and downregulation on downstream signaling and biological
processes such as cellular migration and proliferation.
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